LABAs No Better Than Tiotropium in Black Adults With Asthma

This article originally appeared here.
Share this content:
LABAs No Better Than Tiotropium in Black Adults With Asthma
LABAs No Better Than Tiotropium in Black Adults With Asthma

WEDNESDAY, Oct. 28, 2015 (HealthDay News) -- For black patients with asthma treated with inhaled corticosteroids (ICS), outcomes are similar with addition of tiotropium and long-acting β-agonists (LABAs), according to a study published in the Oct. 27 issue of the Journal of the American Medical Association.

Michael E. Wechsler, M.D., from Brigham and Women's Hospital in Boston, and colleagues conducted a multisite study to compare the effectiveness and safety of tiotropium versus LABAs when used with ICS in black adults with asthma. Patients received ICS plus once-daily tiotropium (532 patients) or twice-daily LABAs (538 patients).

The researchers found that the time to first exacerbation did not differ for LABA + ICS versus tiotropium + ICS (rate ratio, 0.90; 95 percent confidence interval, 0.73 to 1.11; P = 0.31). No difference was seen in the change in forced expiratory volume in one second between the groups at 12 months (between-group difference, 0.020; P = 0.33) or 18 months (between-group difference, 0.025; P = 0.49). No between-group differences were seen in the Asthma Control Questionnaire score at 18 months (between-group difference, 0.04; P = 0.70). Other patient-reported outcomes also did not differ between the groups. Arg16Gly ADRB2 alleles were not associated with the effects of tiotropium + ICS versus LABA + ICS (P = 0.97).

"These findings do not support the superiority of LABA + ICS compared with tiotropium + ICS for black patients with asthma," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease


More in Home

Insulin Glargine, Lixisenatide Combo Beneficial in T2DM

Insulin Glargine, Lixisenatide Combo Beneficial in T2DM

Improved achievement of glycemic targets, reduced body weight

European, American Guidelines Lead to Different Recs for Statins

European, American Guidelines Lead to Different Recs for ...

Quantification of CAC score can improve stratification for those at high, low risk for events

Hyperbaric O2 Therapy Effective in Maxillary Osteoradionecrosis

Hyperbaric O<sub>2</sub> Therapy Effective in Maxillary Osteoradionecrosis

Positive clinical outcome with HBOT for 85.7 percent of patients with maxillary bone osteoradionecrosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »